China FDA Expands Clinical Data Witch Hunt To CROs, Study Sites
This article was originally published in PharmAsia News
Executive Summary
Drug manufacturers in China were firstly required to conduct self-audits of the clinical data submitted to support their product approval applications, then clinical sites were asked to improve study oversight. Now, contract research organizations seem to have become the latest target as the China FDA expands a crackdown on clinical data forgery in which it seemingly considers a 20% failure rate not sufficient.
You may also be interested in...
Stay Or Exit? Global Health Players Ponder New China Trajectory
It's again the time of year when global CEOs descend on China's capital to discuss strategies. This year, however, the mood is different.
Chinese Language Podcast: BIOSECURE Act, US PD-1 Approval, ADC Updates
Guest speaker and lawyer Kevin Duan joins Brian Yang and Dexter Yan to discuss the planned US BIOSECURE Act, the US approval of BeiGene's anti-PD-1 drug and the latest antibody-drug conjugates in development at Chinese pharma firms.
China Biotechs, CDMOs Embrace Uncertain Future, New Options Amid WuXi Woes
The shockwave of WuXi's withdrawal from BIO is ripping through the Chinese contract services sector. While some remain hopeful, others are preparing Plan B.